What is the Fiscal Year for Botanix Pharmaceuticals?

Headquarters

Melbourne, VIC

Industry

Pharmaceutical Manufacturing

Stock Symbol

BOT

Website

Description

Botanix Pharmaceuticals Limited is an ASX-listed (ASX:BOT) dermatology company with its US headquarters in Phoenix, AZ, that is committed to the development and commercialisation of novel treatments for common skin diseases. In June 2024, Botanix received FDA approval for Sofdra, its product for the treatment of excessive underarm sweating (primary axillary hyperhidrosis), and successfully launched it in the US in February 2025. Sofdra is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition. Primary axillary hyperhidrosis is a medical condition where excessive sweating occurs beyond what is needed to maintain body temperature, which impacts the lives of approximately 10 million people in the US alone. Botanix has attracted a world-class team and significant capital to support the commercialization of Sofdra.